Summary of key achievements and milestones

2004

· Delivered the 6 compounds as specified to Fujisawa

· PG2 patent granted in China (4Q)

· PG2 launched in China (4Q)

2003

· Sign extension Agreement with Fujisawa (4Q)

· Start Phase I Clinical Trials for TriptoSar with PFM in Europe (4Q)

2002

· Enroll patients for Phase I Clinical Trials in USA for TriptoSar (2Q)

· Sign Option Agreement with Fujisawa regarding WilGraf (3Q)

· Sign license agreement with PFM regarding TriptoSar (4Q)

2001

· PG2 Clinical Trial initiated in Taiwan (2Q)

· NDA approval for PG2 in PRC (3Q)

· Signature of out-licensing letter of intent with regards to TriptoSar (2Q)

· IND filing for TriptoSar in USA (3Q)

2000

· Creation of a manufacturing JV of Orchid Sarl in Tianjin (1Q)

· PG2-2000 Provisional Patent filed (2Q) in U.S.

· PG2 PCT Patent filed (2Q) in U.S.

1999

· Significant new funding (1Q)

· Creation of PhytoHealth in Taiwan (1Q)

· PG2 Provisional Patent filed (2Q)

· PG2 clinical trials completed in PRC (4Q)

1998

· PCT Patent Application filed for TriptoSar

· US Patent filed for WilGraf

1997

· Pharmagenesis, Inc. received patent in U.S. on PG490-88 (3Q)

· Clinical study on PG2 in China is initiated (3Q)